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AIMS: The anti-neutrophilic cytoplasmatic autoanti-
body-associated vasculitides (AASV) are diseases of
relapsing 
/remitting inflammation. Here we explore
the cytokine profile in different phases of disease,
looking for pathogenic clues of possible prognostic
value.
Results: Interleukin (IL)-6, IL-8 and IL-10 were signi-
ficantly elevated in plasma. Patients in the stable
phase who subsequently developed adverse events
had higher IL-8 values. Patients in the stable phase
who relapsed within 3 months had lower IL-10 values
and higher IL-6 levels.
Conclusions: Patients with AASV have raised circulat-
ing cytokine levels compared with healthy controls,
even during remission. Raised IL-8 seems associated
with poor prognosis. Lower levels of IL-10 and higher
levels of IL-6 herald a greater risk of relapse. Patients
with systemic vasculitis in clinical remission have
persistent disease activity, kept under control by
inhibitory cytokines.
Key words: Vasculitis, Interleukin-6, Interleukin-8, Inter-
leukin-10, Anti-neutrophilic cytoplasmatic autoantibodies,
Inﬂammation, Autoimmunity
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Introduction
Anti-neutrophilic cytoplasmaticautoantibody(ANCA)-
associated small vessel vasculitis (AASV) is a group of
inflammatory disorders, characterized by inflamma-
tion and necrosis of blood vessels and frequently
granuloma formation.
1 These patients make autoan-
tibodies against proteins present in the granules of
neutrophils and monocytes, mainly proteinase 3
(PR3) and myeloperoxidase (MPO).
2 The disorders,
including Wegener’s granulomatosis (WG) and mi-
croscopic polyangiitis, have a relapsing /remitting
progression and a high mortality if untreated. The
pathogenesis is still poorly understood. Proinflam-
matory cytokines, such as tumor necrosis factor
(TNF), interleukin (IL)-1b, and IL-8, have been found
to be elevated systemically and locally at inflamma-
tory sites in WG.
3 6 Moreover, a pathogenic role has
been attributed to IL-8 in ANCA-associated glomer-
ulonephritis.
4
As the ANCA titer correlates well with disease
activity in some studies,
7,8 a pathogenic role for these
autoantibodies has been implicated. In vitro studies
have shown ANCA-induced activation of neutrophils
as well as monocytes.
2 In vitro studies on monocytes
have shown increased release of IL-8, MCP-1, TNF-a,
IL-1b, IL-6 and thromboxane A2 upon stimulation
with ANCAs.
9 13 These studies have been exclusively
performed on peripheral blood monocytes isolated
from healthy donors. Monocytes are an integral part
of granulomas and glomerular crescents in active
AASV,
1,12 and are therefore of importance in under-
standing the pathogenesis of AASV. The extent of
monocyte activation, measured by soluble products
of monocyte activation such as neopterin and IL-6,
has in one study been found to correlate with the
disease activity in WG.
13
In this study, our aim was to further elucidate the
circulating cytokine profile in AASV in stable remis-
sion as well as in different degrees of activity. Our
main objectives were: (1) to find clues to the
pathogenesis of these diseases and (2) to discern
specific cytokine patterns associated with the prog-
nosis. In an earlier study we found raised circulating
levels of IL-6 in combination with normal levels of
sTNFr1.
14 Raised IL-6 levels seemed to be associated
with poor prognosis and increased relapse tendency.
Here we have chosen to look further into IL-6-levels
in plasma, together with the neutrophil chemoattrac-
tant IL-8, the monocyte chemoattractant MCP-1, the
monocyte activation marker neopterin and the more
anti-inflammatory cytokine IL-10. We have also
studied the mRNA expression of IL-6, IL-8 and IL-10
in peripheral blood monocytes isolated from 19
patients with AASV in different phases.
Methods
Patients
Cohort 1 consisted of 59 patients with AASV, accord-
ing to the Chapel Hill Consensus Conference disease
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275definition, that were included in a cross-sectional
study in 1996. The patients were then followed
clinically for 6 years, as has been described earlier.
15
The main focus in this study is on cohort 2 (Table 1).
Between February 2001 and March 2003, every
patient with defined AASV that came to our clinic
was invited to be included. Our exclusion criteria
were dialysis treatment, bacterial or viral infections
and cancer. Based on clinical observations performed
by their regular doctors at the Department of
Nephrology, Lund University Hospital, the patients’
initial status was classified as remission (Birmingham
Vasculitis Activity Score [BVAS] 0 /1), chronic grum-
bling activity (BVASB /5) or new activity. The latter
group was subdivided into minor (BVASB /5) or
major relapse (BVAS  /5). The patients were mon-
itored during 2 years at their regular visits to the
clinic. Clinical status, BVAS, relapses as well as the
development of any severe organ damage (cerebro-
vascular catastrophe, acute myocardial ischemia,
renal failure, subglottic stenosis), started dialysis or
death due to vasculitic complications was registered.
These observations were made without access to the
results of our analyses. The patients were grouped
according to ANCA specificity (PR3 or MPO, PR3  /
MPO, seronegative) as well as development of severe
organ damage or not, and relapse within 3 months of
sampling or not.
In principle, the data presented in tables and
figures are based on the index sample of each
patient. However, all relapse samples and samples
from patients who developed relapse within 3
months (index samples as well as later samples)
have been included. Without this enrichment, the
groups would have been too small to compare. There
is only one sample from each patient in each group.
However, due to the enrichment already described,
different samples from the same patient can, very
occasionally, occur in different groups. The data from
the longitudinal analyses are not shown due to
simplicity, but are described in the text. Our control
group consisted of 30 healthy blood donors (HBD).
From 19 patients with AASV and 11 HBD a blood
sample was taken for isolation of peripheral
blood monocytes and RNA extraction. These studies
were performed with the permission of the Ethical
Committee, Lund University and the written informed
consent of the patients.
Blood samples
Twelve milliliters of venous blood was obtained from
each subject in ethylenediamine tetraacetic acid
(EDTA) tubes and centrifuged within 1 h. Plasma
was carefully aspirated with a Pasteur pipette and
stored at   /208C until assayed. For monocyte isola-
tion, 48 ml of venous blood from each subject was
obtained in EDTA tubes. The blood was kept at 48C.
First, 36 ml was immediately taken and put into
monocyte purification. The remaining 12 ml were
centrifuged within 1 h and plasma aspirated.
IL-6, IL-8, IL-10 and MCP-1
A quantitative sandwich enzyme immunoassay from
R&D systems (Abingdon, UK), where a monoclonal
antibody specific for IL-6, IL-8, IL-10 or MCP-1 had
been pre-coated onto a microplate, was used. Assay
Diluent RD1A and Standard or sample was added to
each well and left to incubate for 2 h at room
temperature. The plates were washed four times to
eliminate any unbound substances. Then conjugate
(a polyclonal antibody conjugated to horseradish
peroxidase) was added to each well for detection of
the cytokine. After 2 h incubation at room tempera-
ture, the plates were washed four times and substrate
solution was added to each well. Twenty minutes of
incubation at room temperature allowed color devel-
opment in proportion to the amount of cytokine
bound in the initial step. Finally, stop solution was
added to each well and the intensity of the coloring
measured. The absorbance was read at 450 nm and
570 nm (correction wavelength).
Neopterin
A competitive enzyme immunoassay from IBL Ham-
burg (Hamburg, Germany), where a peroxidase-
conjugated antigen competes with a non-conjugated
antigen for a fixed number of antibody-binding sites,
was used. The enzyme-linked immunosorbent assay
plates had been pre-coated with goat-anti-rabbit
Table 1. Patient characteristics
Remission Grumbling New activity Minor Major
Patients (n) 6 82 62 11 01 1
MPO/PR3/MPO  /PR3/seronegative 19/43/1/5 9/14/1/2 5/13/1/2 2/6/1/1 3/7/0/1
Females/males 29/39 14/12 8/13 5/5 3/8
Age (range) (years) 63 (19 /88) 65 (26 /82) 60 (26 /83) 59 (31 /83) 61 (26 /82)
Relapse within 3 months (n)6 5  /  /  /
Organ damage (n) 1 2 5513
Grumbling, chronic smoldering activity; minor, new smoldering activity; major, acute relapse; MPO, anti-myeloperoxidase /ANCA-positive
patients; PR3, anti-proteinase 3 /ANCA-positive patients; seronegative, ANCA-negative WG; relapse, new or worsened disease activity; organ
damage, severe organ damage, start in dialysis or death due to vasculitic complications.
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together with enzyme-conjugated neopterin and
rabbit neopterin antiserum and left to incubate for
90 min at room temperature. After washing, substrate
solution was added and finally, after 10 min incuba-
tion, the stop solution was added. Absorbance was
measured at 450 nm and 570 nm (correction wave-
length). The optical density was inversely propor-
tional to the neopterin concentration of the sample.
Cystatin C, C-reactive protein and white
blood cell
Cystatin C was measured as a marker of glomerular
filtration.
16 C-reactive protein (CRP) is a conventional
marker of inflammation.
The Clinical Chemical Laboratory at Lund Univer-
sity Hospital, Lund, Sweden performed analyses on a
Hitachi 917 Pluto (Hitachi, Tokyo, Japan). Kits from
Roche Diagnostics (Basel, Switzerland) and Dako
were used (Glostrup, Denmark).
ANCA
Wieslab AB (Lund, Sweden) performed analyses of
PR3-ANCA and MPO-ANCA by routine methods.
17
Cell separation
Peripheral blood monocytes were isolated by means
of a monocyte isolation technique based on the
OptiPrep density-gradient medium (Axis-Shield PoC
AS, Oslo, Norway).
18 The method is carried out at
48C, under sterile conditions, using sterile solutions.
Briefly, OptiPrep working solution was added to
whole blood. A centrifugation gradient was created
by mixing OptiPrep working solution and solution B
(Dubecco’s modified Eagle’s medium cell medium
with 10% serum; Invitrogen, Carlsbad, CA, USA). Five
milliliters of blood was pipetted into a 15 ml test tube,
after that a 5 ml gradient was carefully added and,
finally, 0.5 ml of solution B on top (in order to avoid
banding of the cells at the liquid /air interface).
During the subsequent centrifugation (700  /g,
30 min, 48C, no brake during deceleration) the
monocytes float to the top of the gradient layer. After
collection, the cells were gently diluted with 2 vol of
solution B, harvested by centrifugation and resus-
pended in solution B. Then 25 ml of cell suspension
was mixed with Tu ¨rk’s solution (methyl-violet) and
counted in a Bu ¨rker chamber. A cell smear from
each sample was also stained with May /Gru ¨newald
for differential counting. The monocyte purity was
80 /85%, with 15 /25% lymphocytes.
RNA extraction
Total RNA was extracted with the RNeasy Mini kit
(VWR International, West Chester, PA, USA) using the
supplied protocol. Briefly the monocytes were homo-
genized and lyzed in the presence of a denaturing
guanidine isothiocyanate-containing buffer, which
immediately inactivates RNases. Then 70% ethanol
is added to provide appropriate binding conditions,
and the sample is then added to an RNeasy mini
column with a silica-gel membrane, which binds
total RNA. After washing, RNA is eluted in RNase
free water. High purity and good integrity were
determined in two ways. First, by optical density,
260/280 nm spectrophotometric ratios, and then
by the Agilent 2100 Bioanalyzer, using the RNA
6000 Nano Assay reagent kit (Agilent Technologies,
Palo Alto, CA, USA). After adding a gel /dye mix
together with the RNA sample (25 /500 ng) to the
RNA 6000 Nano Chip channel system, the bioanalyzer
uses electrophoretic and electroosmotic forces to
drive fluids through capillaries to produce a virtual
gel image and an electropherogram. In the electro-
pherogram, RNA of good quality appears with clear
18 S and 28 S rRNA peaks and a flat baseline, whereas
in the gel you see the corresponding sharp bands */
the larger ribosomal band being more intense. Only
RNA samples that met these criteria were accepted for
further analyses.
Quantitative polymerase chain reaction assay
Total RNA was transcribed into cDNA, using the
Taqman Reverse Transcription Reagents kit (Applied
Biosystems, Foster City, CA, USA), according to the
manufacturer’s recommendations. Briefly, random
hexamers were used as template and put into the
mastermix together with MultiScribe Reverse Tran-
scriptase, RNase inhibitor, dNTPs, MgCl2 and reverse
transcription buffer. Then 500 ng total RNA was
added in each 50 ml reaction. For determination
of gene expression, quantitative polymerase chain
reaction assays were performed on an ABI PRISM
7000 Sequence Detector (Applied Biosystems) with
Taqman Universal Master Mix UNG, using the stan-
dard conditions determined by the company. Assay
on Demand, a unique combination of forward and
reverse primers and fluorescent MGB probes de-
signed by the company, was used for each target
gene. b-Actin expression levels were used for nor-
malization. Ten nanograms of RNA was used per
25 ml reaction and each reaction was performed in
triplicate. The level of expression was calculated
based upon the polymerase chain reaction cycle
number (Ct) at which the exponential growth in
fluorescence from the probe passes a certain thresh-
old value. Relative expression was determined by the
difference in the Ct values for the target genes after
Cytokine levels in ANCA-associated vasculitis
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values. Relative quantification was determined by
standard 2
( DDCt) calculations.
19 Data are presented
in relation to the median value of the HBD, set as 1.
Statistical analysis
All statistics were performed in StatView 5.01. For
correlation analysis, the non-parametric Spearman
rank correlation test was used in order to reduce the
impact of outliers. Analysis of variance was carried
out using the non-parametric Kruskal /Wallis test and
the Mann /Whitney U-test.
Results
Interleukin-6
In the cross-sectional study we found elevated levels
of IL-6 in AASV in remission.
15 During the 6-year
follow-up period, 26 out of 59 patients experienced
relapse and 24 patients developed severe organ
damage. Patients who subsequently developed re-
lapses had as a group somewhat raised concentra-
tions compared with those who did not (median
values, 5.7 ng/l versus 2.8 ng/l, pB /0.05). Patients
who developed organ damage had a median IL-6 of
4.4 ng/l, compared with 2.0 ng/l for those who did
not (pB /0.05). Some correlation was seen with
cystatin C, indicating decreased renal elimination.
The differences were, however, to some extent
maintained after division by cystatin C. The ANCA
titer did not seem to matter, except that in patients
with MPO-ANCA the IL-6 levels and prognosis
tended to have stronger correlation than in patients
with PR3-ANCA, especially after correction for de-
creased renal function. These findings prompted us
to start a longitudinal study.
All samples collected in the longitudinal study as
presented in Table 1 were analyzed for IL-6. We
found significantly raised circulating levels of IL-6 in
patients with AASV in the active phase as well as in
remission compared with HBD (pB /0.0001) (Table 2
and Fig. 1). Patients in remission and patients with
grumbling disease activity or minor relapses had
similar IL-6 levels. Patients with major relapses, on
the other hand, had significantly higher plasma levels
(pB /0.001). Patients in the stable phase (either
remission or grumbling activity) with severe organ
damage during the follow-up period had significantly
raised IL-6 levels (4.8 ng/l [1.3 /18.8] versus 2.6 ng/l
[undetermined /34.3], pB /0.05; Fig. 2). Also, when
looking at patients who did or did not develop
relapse within 3 months from sampling, IL-6-
levels were significantly higher in the former group
(5.3 ng/l [2.1 /17.5] versus 2.6 ng/l [undetermined /
31.8], pB /0.05; Fig. 3). Repeated measurements
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278 Mediators of Inflammation Vol 13  2004showed intra-individual variation, somewhat corre-
lating to disease activity but with a tendency of rising
IL-6 levels prior to relapse. Just like in the cross-
sectional study, a positive correlation was seen
between IL-6 and cystatin C (Table 3). After division
by cystatin C, the raised IL-6 levels in patients who
developed organ damage (renal damage was the
most common organ damage) was no longer sig-
nificant. This phenomenon argues against IL-6 as an
important mediator of organ damage, although this
cannot be ruled out completely.
20 IL-6 as a predictor
of relapse was, however, strengthened by cystatin C
division (pB /0.001 compared with pB /0.05), indicat-
ing a pathogenic role. The other differences de-
scribed were maintained even after division by
cystatin C. ANCA titer and specificity had no obvious
connection with the IL-6 levels, whereas the correla-
tion between IL-6 and CRP was strong (Table 3). The
raised IL-6 levels shown here are moderate, since IL-6
in sepsis reaches 200 /2000 ng/l.
21
Interleukin-8
One-half of the samples from the longitudinal study
were randomly subjected to additional analyses. As
shown in Fig. 1, IL-8 was significantly elevated in all
patient groups, compared with HBD (pB /0.05). The
levels were higher in patients with relapse, regardless
of severity, than in patients in stable phase (pB /0.05)
(Table 2). Patients in the stable phase (either remis-
sion or grumbling activity) who developed organ
damage during the follow-up had higher levels of IL-
8 than those who did not (21.5 ng/l [11.5 /66.6] versus
9.8 ng/l [undetermined /4.6], pB /0.0001; Fig. 2). In
the group that developed relapse within 3 months,
elevated IL-8 levels were seen compared with those
who did not (16.4 ng/l [undetermined /28.8] versus
FIG. 2. Circulating cytokine levels in vasculitis patients in
stable phase, separated according to subsequent develop-
ment of severe organ damage during the follow-up period.
, results from 17 patients who did develop organ damage
during the follow-up period; , results from 38 patients were
no adverse event was observed (for 77 IL-6 patients); ,
healthy control group.
FIG. 3. Circulating cytokine levels from vasculitis patients in
the stable phase, separated according to subsequent devel-
opment of overt relapse. , results from 11 patients who did
relapse within the following 3-month period; , results from
40 patients where no relapse was detected for at least 3
months (for 80 IL-6 patients); , healthy control group.
FIG. 1. Circulating cytokine levels from patients with ANCA-
associated vasculitis, separated according to disease activity.
, results from patients in remission; , results from patients
with grumbling disease; , patients with minor relapse; ,
patients with major relapse; , healthy control group. *, **,
***Signiﬁcant p values, relative to controls (pB /0.05,
pB /0.01, pB /0.001, respectively) when using the Mann /
Whitney U-test.
Cytokine levels in ANCA-associated vasculitis
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not statistically significant (Fig. 3). Repeated measure-
ments showed intra-individual variation, correlating
to some extent with clinical disease activity. IL-8
showed no correlation with either CRP or ANCA titer
and only a weak correlation with cystatin C (Table 3).
Nor did ANCA specificity seem to matter. For
comparison, IL-8 reaches 200 /2000 ng/l in sepsis.
22
Interleukin-10
IL-10 was analyzed in the same set of samples as IL-8.
As shown in Fig. 1, IL-10 levels were virtually the
same, regardless of disease activity (Table 2). No
difference was seen between IL-10 levels in patients
in the stable phase (either remission or grumbling
activity) who did or did not develop organ damage
during follow-up (Fig. 2). As shown in Fig. 3, patients
who experienced relapse within 3 months of
sampling tended to have lower levels of circulating
IL-10 than the other patients (7.0 ng/l [5.6 /15.5]
versus 13.0 ng/l [4.4 /57.9], pB /0.05). Repeated
measurements showed some intra-individual varia-
tion, irrespective of disease activity. Prior to relapse,
five out of 10 patients had persistently lower IL-10
values, three fell and two rose. Just like IL-8, IL-10
showed no correlation with either CRP or ANCA titer
(Table 3). Nor did renal function or ANCA specificity
seem to matter. IL-10 has in sepsis been reported
increased to around 20 ng/l.
22 A recently published
study, however, showed low IL-10 levels (median,
1.5 ng/l; range, 0.1 /6.9 ng/l) in critically ill patients
with sepsis development.
23
MCP-1
The monocyte chemoattractant MCP-1 was analyzed
in the same set of samples as IL-8 and IL-10. No
elevation was seen in patients with AASV in the stable
phase compared with HBD (157 ng/l [54 /345] versus
153 ng/l [72 /295]). Nor were there any increased
values in patients with relapse. No differences were
found regarding development of organ damage and
relapses or not. Strong positive correlation was seen
between MCP-1 and cystatin C, indicating an influ-
ence of decreased renal filtration. As is also presented
in Table 3, no correlation was seen with either CRP or
ANCA titer.
Neopterin
Neopterin is a marker of monocyte activation,
24
measured in 40 of the samples in the longitudinal
study. It was significantly raised in AASV in the stable
phase, compared with HBD (8.0 nmol/l [4.5 /13.7]
versus undetected), but no difference was seen
between different degrees of activity. Nor was there
any difference with regard to development of organ
damage or relapses. What we did find, as presented
in Table 3, was a very strong positive correlation with
cystatin C. As is also presented in Table 3, no
correlation was seen with either CRP or ANCA titer.
Taken together, the raised neopterin levels did not
seem to depend on increased monocyte activation,
but rather on decreased elimination.
sTNFr1
Another marker of monocyte activity and also of the
TNF/TNF-receptor system is sTNFr1.
25 This protein
was measured in the cross-sectional study (cohort 1)
and was found to be significantly elevated in AASV
compared with HBD (2.9 mg/l [0.9 /23.9] versus
1.1 mg/l [0.8 /2.1], pB /0.05). Just as for neopterin,
the elevated levels could, however, be explained by
decreased renal function. Cystatin C correlated
strongly with sTNFr1 (r  /0.5, pB /0.0001), and after
division by cystatin C there was no difference
between AASV and HBD.
15
Monocytes as a potential source
Considering monocytes as a potential source of the
upregulated cytokines IL-6, IL-8 and IL-10, peripheral
blood monocytes were purified from 19 patients
with AASV and 11 HBD. Twelve patients were in
stable remission, five patients had chronic grumbling
activity and two patients had acute relapse. All data
were compared with and expressed in relation to the
median HBD, set as standard (  /1). IL-6-expression
tended to be lower in AASV than in HBD, but the
expression levels were overall very low and data
therefore too uncertain to interpret, but contradicting
an unspecific activation of the cells during the
purification process. As for IL-8 and IL-10, the
patients demonstrated somewhat increased expres-
sion compared with HBD (Table 4), although the
Table 3. Correlation matrix
BVAS ANCA Cystatin C CRP Neopterin MCP-1 IL-10 IL-8
IL-6 0.2, ns 0.2, ns 0.4*** 0.5*** 0.5* 0.5*   /0.1, ns 0.3*
IL-8 0   /0.3, ns 0.4* 0.2, ns 0.4, ns 0.5* 0
IL-10 0.1, ns 0.2, ns 0 0   /0.2, ns   /0.2, ns
MCP-1 0 0.1, ns 0.7*** 0 0.6, ns
Neopterin 0.4, ns 0.2, ns 0.7*** 0.3, ns
The correlations are expressed as Rho: *pB /0.05, **pB /0.001, ***pB /0.0001; ns, not significant, p  /0.05, using the non-parametric Spearman
correlation test. 0  /RhoB /0.1.
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correlation (r
2  /0.3) between circulating levels of IL-
8 and monocyte IL-8 mRNA levels, although non-
significant (Fig. 4). No such correlation was seen
for IL-10. Thus monocytes are a potential source of
circulating IL-8 and perhaps also IL-10 in AASV,
whereas IL-6 seems to have a different origin.
Discussion
AASV is characterized by relapsing /remitting inflam-
mation in the small vessels, and prominent infiltrates
of neutrophils and monocytes are seen in the vessel
wall.
1 Although there is a strong association with the
presence of ANCAs,
2 the pathogenic role of these
antibodies has not yet been completely delineated.
Some patients have persisting high ANCA titers when
in clinical remission, indicating that ANCA alone is
not enough to induce disease. In an earlier study, we
found raised circulating levels of IL-6, which to some
extent were associated with poor prognosis and
increased relapse tendency.
14 In this study, our aim
was to further elucidate the cytokine pattern in the
circulation of patients with AASV. Our intention, in
the long run, is to find specific patterns with
prognostic value and to discern pathogenic clues.
In this study we also investigate the monocyte as a
potential cytokine source, exploring its role as a
central character in the scheme of pathogenesis. Our
main finding is that circulating cytokine patterns in
patients with ANCA-associated vasculitis in stable
remission differ compared with healthy controls.
Even during remission patients have raised circulat-
ing levels of IL-6, IL-8 and IL-10. High IL-8 levels
seem to be associated with poor prognosis, whereas
lower levels of IL-10 and higher levels of IL-6 could
herald a greater risk of relapse.
Earlier studies within this field are relatively scarce
and have largely focused on patients with acute
exacerbation.
3 6 In a recently published study by
Wikman et al.
26 plasma as well as monocytes from
patients with newly diagnosed acute anti-PR3-posi-
tive vasculitis was compared with patients with acute
infection and healthy controls. Increased plasma
levels of IL-6, sTNFr1, IL-10 and IL-8 were shown in
both disease groups, whereas MCP-1 levels were
similar to those in healthy controls. The monocytes
showed a reduced capacity to produce oxygen
radicals, which together with lower circulating levels
of sCD14 and IL-6 than in patients with acute
infection, could be a consequence of prolonged
immune activation. This would be well in line with
our findings, showing that even patients in stable
remission have significantly elevated plasma levels of
IL-6, IL-8 and IL-10, within the same range as patients
who have chronic, grumbling activity. The patients
usually have varying doses of immunosuppressants,
which could affect the results. In this study 25
samples from patients with no immunosuppressive
treatment at all were included and did not differ from
the rest in our analyses (data not shown). Decreased
renal filtration could have some influence on IL-6
levels, whereas IL-8 and IL-10 did not seem to be
affected.
We also wanted to explore potential variations in
cytokine expression profile in relation to patient
outcome. High IL-6 levels were associated with
development of permanent organ damage (although
non-significant after correction for decreased renal
filtration) as well as relapse tendency (pB /0.001).
Many have implicated IL-6 in the development of
atherosclerosis.
27 The finding of persisting high levels
of circulating IL-6 is therefore consistent with an
increased risk of atherosclerotic complications in
these patients.
28 IL-10, on the other hand, has a
counterbalancing capacity and the IL-10 genotype is
predictive of the risk of cardiovascular disease in
end-stage renal disease.
29 In this context, possible
chronic monocyte activation is of course of interest,
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FIG. 4. Correlation between plasma concentration and
monocyte mRNA levels from 19 patients with ANCA-asso-
ciated vasculitis with different disease activity. Plasma levels
were measured (ng/l) using an enzyme-linked immunosor-
bent assay. mRNA levels are normalized using b-actin as
house keeping gene and the median value of the healthy
controls is set to 1.0. The correlation coefﬁcient is 0.374, non-
signiﬁcant.
Table 4. Monocyte expression of IL-8 and IL-10
IL-8 mRNA
expression
IL-10 mRNA
expression
AASV (n  /19) 2.8 (0.2 /36) 2.2 (0.4 /8.8)
MPO-positive (n  /6) 6.0 (1.0 /17) 2.2 (0.8 /5.6)
PR3-positive (n  /12) 1.9 (0.2 /36) 2.2 (0.4 /8.8)
Seronegative (n  /1) 2.0 0.9
HBD (n  /11) 1.0 (0 /230) 1.0 (0.3 /4.0)
MPO-positive, patients with positive MPO-ANCA; PR3-positive,
patients with positive PR3-ANCA. The real-time data are corrected
according to the 2
( DDCt) formula and are then expressed in relation
to the median value of the healthy controls. Results are presented as
median (range).
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development of atherosclerotic plaques.
28
Monocyte activation in AASV has mainly been
attributed to the influence of ANCA,
13,26 although
surface PR3 expression on monocytes, in contrast to
that on neutrophils, does not correlate with disease
activity.
30 In our studies we have not been able to
confirm any marked monocyte activation. Although
increased circulating levels of IL-6, mRNA levels in
monocytes were hardly detectable. Furthermore,
raised neopterin and sTNFr1 levels in plasma were
largely attributed to decreased renal filtration and
MCP-1 did not differ from healthy controls. Some sort
of persisting low-grade activation of the immune
system, in accordance with the findings of Wikman
et al.
26 seems plausible. One possibility is activation
of the monocytes upon exit from the blood vessels;
another is dysfunctional apoptosis after entrance into
surrounding tissue. Other potential sources of course
include the lymphocytes, which have been impli-
cated in earlier studies.
31
The circulating levels of IL-8, a chemokine that has
been implicated in the pathogenesis of AASV in a
study by Cockwell et al.
4 were significantly higher in
patients with more severe outcome. PR3
32 can induce
IL-8 production in endothelial cells, which is a
possibility here, considering the raised circulating
levels of PR3 shown in an earlier study.
15 Monocyte
expression of IL-8 mRNA was detected and some
correlation was seen with plasma levels.
IL-10 was significantly lower in plasma from
patients who subsequently developed a relapse
compared with patients who did not, indicating that
the counterbalancing properties of IL-10 are neces-
sary in order to retain persistent subclinical disease
activity. Two studies have reported polymorphisms
in the IL-10 gene associated with WG.
33,34 This of
course makes it very interesting to study the IL-10
genotype in these patients and to identify the source.
Monocyte expression of IL-10 mRNA was detected,
but no correlation was seen with plasma levels or
clinical activity. Neither was there any co-variation
between IL-8 and IL-10 mRNA levels
Taken together, our findings indicate that patients
with systemic vasculitis in clinical remission have
persistent subclinical disease activity, kept under
control by inhibitory cytokines. Whether measure-
ments of IL-6, IL-8 or IL-10 could provide useful
clinical information or whether IL-10-mimicking
drugs would prevent relapses are important ques-
tions for the future.
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